Introducing Veranova’s Advisory Board

In October, Veranova announced the appointment of a new Advisory Board, and now we’re giving you the opportunity to get to know our new board members. The advisory team brings a wealth of expertise in the pharmaceutical and CDMO sectors, and we look forward to working with them to advance Veranova’s mission.

Dr Carolyn Bertozzi

Dr Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and a recipient of the 2022 Nobel Prize in Chemistry. She is also the Baker Family Director of Stanford’s Sarafan ChEM-H Institute and an Investigator at the Howard Hughes Medical Institute. Carolyn is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, Accademia Nazionale dei Lincei, the German Academy of Sciences Leopoldina, and a Foreign Fellow of the Royal Society (UK). She is a member of the Board of Directors of Alnylam and OmniAb, Inc. and a former Director of Eli Lilly.

“I am excited to work with the talented team at Veranova, alongside the other Scientific Advisory Board members who are all highly accomplished biopharma veterans. Veranova is positioned to amplify the impact of leading-edge therapeutic modalities, and I hope to support this with my experience as an academic researcher and technology inventor.”

John Nason

John Nason has over 30 years of experience in the manufacturing of complex APIs, biologics and finished dose forms. He was previously President of Teva Pharmaceutical Ingredients (TAPI) and Biologics Operations, Senior Vice President of Teva Global Operations, served as Vice President of External Manufacturing and Alliance Management at Bristol Myers Squibb for over ten years, and led bulk API manufacturing for Novartis.

“I have recently joined the Advisory Board because I feel that my technical and business experience in biotech products and technologies will have a positive impact on the exciting current and future pipeline portfolio. I have always worked to provide patient support and welfare, and that drive will continue in this Board appointment.”

Carlo de Notaristefani

Carlo de Notaristefani is an accomplished executive with over 30 years of experience building and leading some of the most complex supply chains in the pharmaceutical industry. Carlo led manufacturing operations for Operation Warp Speed, the public/private partnership that delivered billions of vaccine doses during the COVID-19 pandemic. He was previously President & CEO of Global Operations for Teva Pharmaceuticals, President of Technical Operations for Bristol Myers Squibb and held multiple senior leadership positions with Bristol Myers Squibb and Aventis.

“In my long career in pharma operations I have helped many companies deliver the treatments patients need around the world. I am excited to be able to help Veranova management team in their mission, becoming the partner of choice for their customers, and delivering new treatments to patients.”


Edward Robinson

Edward Robinson is an accomplished executive with over 30 years of experience building and growing businesses in the CDMO industry. He served as President of Lonza Biologics where he was instrumental in launching Lonza’s US operations. Ed served as Executive Vice President of Cambrex, President of Solutia Pharmaceutical Services, Vice President of Genencor International, and held multiple leadership positions with Snomax Technologies and Eastman Kodak.

“I am delighted to join the Veranova team. Mike Riley has a fine track record in building world class businesses and I’m certain Veranova is positioned for great success.”

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us